BSE filing, NSE: NEOGEN. Summary written from the filing by ALFA Finder's alert engine.
Neogen Chemicals Ltd: key numbers
- Share price
- ₹2,548.60
- Market cap
- ₹7,657 Cr
- Revenue (annual)
- ₹862.0 Cr
- Net profit (annual)
- ₹28.75 Cr
- P/E (TTM)
- 189.4×Sector 28.2×
- Promoter holding
- 48.31%-4.70% QoQ
- FII holding
- 4.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neogen Chemicals Ltd
All →Neogen Chemicals Other Announcement
A HUF of a director of Neogen's wholly owned subsidiary sold 2,361 shares on 5-6 November 2026. Sale consideration totals about ₹0.59 crore.
- Value
- ₹0.59 Cr
Neogen Chemicals Annual General Meeting
Neogen Chemicals seeks shareholder approval via postal ballot for related party transactions with a step-down subsidiary. E-voting runs until December 6, 2026.
Neogen Chemicals Earnings Call Transcript: Key Takeaways
Revenue rose 42% to ₹296 Cr and consolidated PAT rose 144% to ₹8 Cr, but a large standalone-to-consolidated gap shows the Neogen Ionics drag. Net debt is ₹1,095 Cr, and management gave no hard quarterly target to test against.
Neogen Chemicals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue INR 296 Cr (+42%), EBITDA INR 45 Cr (+51%), PAT INR 8 Cr (+144%). Battery Chemicals revenue INR 37 Cr; Organolithium capacity expansion approved.
Neogen Chemicals Results Update
Neogen Chemicals issued its Q2 FY27 press release on unaudited results, showing higher year-on-year revenue and profit. Battery chemicals ramp-up and the QIP proceeds featured prominently.
Neogen Chemicals Debt & Borrowing: ₹500 Cr
Neogen Chemicals approved in-principle a Rs 500 Crore corporate guarantee for Neogen Morita's borrowings, subject to shareholder approval. The company reports no adverse impact.
- Value
- ₹500.0 Cr
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.